Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Amylyx Pharmaceuticals, Inc.’s reported figures.
The source filing: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:04 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336682
FAQ
- What is Amylyx Pharmaceuticals, Inc.'s EBIT?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported EBIT of -$45.69M in Q2 2026.
- How has Amylyx Pharmaceuticals, Inc.'s EBIT changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s EBIT decreased by 6.6% year-over-year, from -$42.86M to -$45.69M.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s EBIT has grown at a 16.7% compound annual growth rate (CAGR), from -$82.69M to -$153.29M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Amylyx Pharmaceuticals, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude